## Andrea Belluzzi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6877866/publications.pdf

Version: 2024-02-01

236833 182361 2,843 58 25 51 citations h-index g-index papers 58 58 58 3486 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. Digestive Diseases and Sciences, 2021, , 1.	1.1	О
2	Omega-3 as a Part of the Dietary Guidance for Patients with Ulcerative Colitis: Beyond the Natural Sources. Clinical Gastroenterology and Hepatology, 2021, 19, 1296-1297.	2.4	1
3	latrogenic Kaposi sarcoma during tumor necrosis factor alpha inhibitors. Italian Journal of Dermatology and Venereology, 2021, 156, 113-114.	0.1	O
4	Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection. Medical Hypotheses, 2020, 143, 110095.	0.8	1
5	Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials, 2019, 20, 327.	0.7	17
6	Simkania negevensis in Crohn's Disease. Digestive Diseases and Sciences, 2019, 64, 3284-3290.	1.1	4
7	A Mediterranean Diet Mix Has Chemopreventive Effects in a Murine Model of Colorectal Cancer Modulating Apoptosis and the Gut Microbiota. Frontiers in Oncology, 2019, 9, 140.	1.3	26
8	Attachment and Mentalizing Abilities in Patients with Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2019, 2019, 1-7.	0.7	18
9	Endoscopic and Histological Normalization as a Target to Prevent Clinical Relapse in Ulcerative Colitis Patients. Inflammatory Bowel Diseases, 2019, 25, e67-e67.	0.9	O
10	Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. Digestive Diseases and Sciences, 2019, 64, 863-874.	1.1	8
11	Omega-3 polyunsaturated fatty acids and IVF treatment. Reproductive BioMedicine Online, 2019, 38, 95-99.	1.1	20
12	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1268-1275.e2.	2.4	42
13	Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch–Anal Anastomosis for Ulcerative Colitis. Digestive Diseases and Sciences, 2017, 62, 1016-1024.	1.1	19
14	A liquid chromatography–tandem mass spectrometry method to measure fatty acids in biological samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1055-1056, 125-134.	1.2	18
15	Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Scientific Reports, 2017, 7, 7458.	1.6	54
16	The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. International Journal of Molecular Sciences, 2017, 18, 2619.	1.8	107
17	Inflammation increases NOTCH1 activity via MMP9 and is counteracted by Eicosapentaenoic Acid-free fatty acid in colon cancer cells. Scientific Reports, 2016, 6, 20670.	1.6	43
18	Different Cutoff Levels of Fecal Calprotectin to Predict Clinical Relapse in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, E26.	0.9	3

#	Article	IF	Citations
19	MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction Syndrome. American Journal of Gastroenterology, 2016, 111, 767.	0.2	7
20	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	0.5	30
21	How to predict clinical relapse in inflammatory bowel disease patients. World Journal of Gastroenterology, 2016, 22, 1017.	1.4	107
22	Clinical application of faecal calprotectin in ulcerative colitis patients. European Journal of Gastroenterology and Hepatology, 2015, 27, 1418-1424.	0.8	24
23	The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid. BioMed Research International, 2015, 2015, 1-8.	0.9	13
24	Acute Fitz-Hugh-Curtis Syndrome in a Man due to Gonococcal Infection. Journal of Emergency Medicine, 2015, 48, e59-e62.	0.3	9
25	Can fecal calprotectin better stratify Crohn's disease activity index?. Annals of Gastroenterology, 2015, 28, 247-252.	0.4	10
26	<i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in the etiology of Crohn's disease, cause or epiphenomenon?. World Journal of Gastroenterology, 2014, 20, 13060.	1.4	54
27	A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. Carcinogenesis, 2014, 35, 2314-2320.	1.3	25
28	Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitisâ€associated colorectal cancer acting on Notch signaling and gut microbiota. International Journal of Cancer, 2014, 135, 2004-2013.	2.3	73
29	Can POSSUM accurately predict post-operative complications risk in patients with abdominal Crohn's disease?. ANZ Journal of Surgery, 2014, 84, 78-84.	0.3	5
30	Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut, 2014, 63, 1760-1768.	6.1	93
31	Asymptomatic and Persistent Elevation of Pancreatic Enzymes in an Ulcerative Colitis Patient. Case Reports in Gastrointestinal Medicine, 2013, 2013, 1-4.	0.2	7
32	Fecal Detection of Mycobacterium avium Paratuberculosis Using the IS900 DNA Sequence in Crohn's Disease and Ulcerative Colitis Patients and Healthy Subjects. Digestive Diseases and Sciences, 2011, 56, 2957-2962.	1.1	33
33	Splenic granulomas in a patient with severe Crohn's disease associated with multiple extraintestinal manifestations. Inflammatory Bowel Diseases, 2011, 17, E35-E37.	0.9	1
34	IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes. International Journal of Molecular Medicine, 2011, 27, 469-77.	1.8	28
35	Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Alimentary Pharmacology and Therapeutics, 2010, 31, 228-232.	1.9	22
36	Prepouch ileitis, myth or reality? The first case with acute abdomen. Inflammatory Bowel Diseases, 2010, 16, 12-14.	0.9	1

3

#	Article	IF	Citations
37	New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1239-1246.	0.9	27
38	Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut, 2010, 59, 918-925.	6.1	201
39	Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice. Clinical Cancer Research, 2010, 16, 5703-5711.	3.2	70
40	Fish oil-based emulsion for the treatment of parenteral nutrition associated liver disease in an adult patient. European E-journal of Clinical Nutrition and Metabolism, 2010, 5, e243-e246.	0.4	21
41	Effect of Eicosapentaenoic Acid on E-type Prostaglandin Synthesis and EP4 Receptor Signaling Human Colorectal Cancer Cells. Neoplasia, 2010, 12, 618-IN2.	2.3	72
42	Intestinal epithelial cells in inflammatory bowel diseases. World Journal of Gastroenterology, 2010, 16, 4264.	1.4	109
43	Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy, 2009, 11, 1020-1031.	0.3	39
44	Inflammatory bowel disease: Moving toward a stem cell-based therapy. World Journal of Gastroenterology, 2008, 14, 4616.	1.4	69
45	Serum protein profiling in patients with inflammatory bowel diseases using selective solidâ€phase bulk extraction, matrixâ€assisted laser desorption/ionization timeâ€ofâ€flight mass spectrometry and chemometric data analysis. Rapid Communications in Mass Spectrometry, 2007, 21, 4142-4148.	0.7	40
46	A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study. World Journal of Gastroenterology, 2007, 13, 1575.	1.4	6
47	n-3 Fatty acids for the treatment of inflammatory bowel diseases. Proceedings of the Nutrition Society, 2002, 61, 391-395.	0.4	92
48	N-3 and n-6 fatty acids for the treatment of autoimmune diseases. European Journal of Lipid Science and Technology, 2001, 103, 399-407.	1.0	9
49	Polyunsaturated Fatty Acids and Autoimmune Diseases., 2001,, 271-287.		5
50	Polyunsaturated fatty acids and inflammatory bowel disease. American Journal of Clinical Nutrition, 2000, 71, 339S-342S.	2.2	189
51	Lipid Treatment in Inflammatory Bowel Disease. , 1999, 2, 199-215.		0
52	n-3 Fatty acids in the treatment of Crohn's disease. , 1998, , 91-101.		4
53	Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease. New England Journal of Medicine, 1996, 334, 1557-1560.	13.9	729
54	Prediction of relapse in patients with CrohnÊ $\frac{1}{4}$ s disease in remission. European Journal of Gastroenterology and Hepatology, 1994, 6, 955-962.	0.8	30

#	Article	IF	CITATION
55	Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. Digestive Diseases and Sciences, 1994, 39, 550-554.	1.1	13
56	Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of x-ray-demonstrated lesions of crohn's disease. Digestive Diseases and Sciences, 1993, 38, 433-437.	1.1	37
57	Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Digestive Diseases and Sciences, 1992, 37, 1890-1897.	1.1	88
58	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Digestive Diseases and Sciences, 1992, 37, 29-32.	1.1	70